Research Papers:

MiR-338-3p inhibits epithelial-mesenchymal transition in gastric cancer cells by targeting ZEB2 and MACC1/Met/Akt signaling

Na Huang, Zhenzhen Wu, Li Lin, Minyu Zhou, Lin Wang, Huanrong Ma, Jianling Xia, Jianping Bin, Yulin Liao and Wangjun Liao _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2015; 6:15222-15234. https://doi.org/10.18632/oncotarget.3835

Metrics: PDF 3110 views  |   HTML 2904 views  |   ?  


Na Huang1, Zhenzhen Wu1, Li Lin1, Minyu Zhou1, Lin Wang1, Huanrong Ma1, Jianling Xia1, Jianping Bin2, Yulin Liao2 and Wangjun Liao1

1 Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China

2 Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China

Correspondence to:

Wangjun Liao, email:

Keywords: gastric cancer; miR-338-3p; ZEB2; MACC1; epithelial-mesenchymal transition

Received: December 14, 2014 Accepted: March 26, 2015 Published: April 14, 2015


MicroRNAs (miRNAs) are involved in the epithelial-mesenchymal transition (EMT) process and are associated with metastasis in gastric cancer (GC). MiR-338-3p has been reported to be aberrantly expressed in GC. In the present study, we show that miR-338-3p inhibited the migration and invasion of GC cells in vitro. Knocking down miR-338-3p in GC cells led to mesenchymal-like changes. MiR-338-3p influenced the expression of the EMT-associated proteins by upregulating the epithelial marker E-cadherin and downregulating the mesenchymal markers, N-cadherin, fibronectin, and vimentin. In terms of mechanism, miR-338-3p directly targeted zinc finger E-box-binding protein 2 (ZEB2) and metastasis-associated in colon cancer-1 (MACC1). MiR-338-3p repressed the Met/Akt pathway after MACC1 inhibition. Reintroduction of ZEB2 and MACC1 reversed miR-338-3p-induced EMT suppression. Consistently, inverse correlations were also observed between the expression of miR-338-3p and ZEB2 or MACC1 in human GC tissue samples. In conclusion, miR-338-3p inhibited the EMT progression in GC cells by targeting ZEB2 and MACC1/Met/Akt signaling.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3835